A recent small study has found that people may be able to maintain their weight loss with fewer GLP-1 injections, but this ...

The small study, published recently in the journal Obesity, looked at 34 patients who had already lost weight on GLP-1 ...

作为先为达生物自主研发的新一代cAMP偏向型GLP-1受体激动剂，埃诺格鲁肽注射液凭借独特的偏向性机制，已在多项临床研究中展现出了优异的疗效与安全性，其中国人群经安慰剂组调整后的平均体重降幅达15.1%，92.8%的患者达到具有临床意义的体重下降，超过80%的患者血糖达标（HbA1c<7.0%）。

The results of this obesity medication are literally eye-popping. A new review of adverse effects reports to the FDA between the years 2017 and 2024 reveals that Ozempic and Wegovy have both been ...

Investing.com -- Eli Lilly plans to invest $3 billion in China over the next decade to build production capacity for its experimental type-2 diabetes and obesity treatment orforglipron, the drugmaker ...

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Ecnoglutide is distinguished by its selective activation of the cAMP signalling pathway, reducing β-arrestin recruitment.

In a recent review, a small group of patients received the injections less frequently but still maintained weight loss and health benefits.

New research is taking a closer look at what can happen when people stop taking GLP-1 medications for a long period of time.

A newly reported side effect of the popular GLP-1 weight loss drugs may be its most annoying yet. From “Ozempic ears” and “Ozempic butt” to “Ozempic breasts” and “Ozempic face,” people have given many ...

据悉根据上述协议，辉瑞将获得该产品在中国大陆的独家商业化权益，迈出其全球代谢领域战略布局在中国的第一步；同时先为达生物为许可产品的药品上市许可持有人（MAH），负责许可产品的研发、注册、生产及供应。先为达生物将有权获得辉瑞支付的最高可达4.95亿美元的付款总额，包括首付款、注册及销售里程碑付款。

Uncrowned is a new destination for all things MMA, boxing, wrestling, and more, featuring Ariel Helwani. But injectable medications aren’t right for everyone. That’s where a new wave of oral GLP-1 ...